A recently published study showed that among patients newly diagnosed with schizophrenia, use of LAI antipsychotics was associated with significantly reduced risks of all-cause mortality and suicide attempts vs oral antipsychotics. Moreover, early treatment with LAIs (within the first 2 years after diagnosis) was also associated with decreased suicide mortality risks, suggesting that consideration of LAIs in the early stage of treatment is merited.
Learn more about the association of LAI antipsychotics and suicide risk.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ravinder N. Bhalla. Fast Five Quiz: Long-Acting Injectable Antipsychotics - Medscape - Aug 19, 2021.
Comments